Page last updated: 2024-09-05

lenalidomide and osi 930

lenalidomide has been researched along with osi 930 in 2 studies

Compound Research Comparison

Studies (lenalidomide)	Trials (lenalidomide)	Recent Studies (post-2010) (lenalidomide)	Studies (osi 930)	Trials (osi 930)	Recent Studies (post-2010) (osi 930)
3,532	725	2,850	27	2	20

Protein Interaction Comparison

Protein	Taxonomy	osi 930 (IC50)
RAF proto-oncogene serine/threonine-protein kinase	Homo sapiens (human)	0.041
Tyrosine-protein kinase Lck	Homo sapiens (human)	0.022
Mast/stem cell growth factor receptor Kit	Homo sapiens (human)	0.0195
Vascular endothelial growth factor receptor 2	Homo sapiens (human)	0.007

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Bockman, J; Rice, MC	1

Other Studies

2 other study(ies) available for lenalidomide and osi 930

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit. IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:10 Topics: Angiogenesis Inhibitors; Benzamides; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cooperative Behavior; Diphenylamine; Drug Industry; Drugs, Investigational; Humans; Lenalidomide; Marketing; Phthalazines; Piperazines; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Stem Cell Factor; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A	2005

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013

Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit.

IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:10

Topics: Angiogenesis Inhibitors; Benzamides; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cooperative Behavior; Diphenylamine; Drug Industry; Drugs, Investigational; Humans; Lenalidomide; Marketing; Phthalazines; Piperazines; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Stem Cell Factor; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A

2005